Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a Shared Neoantigen Cancer Vaccine in Patients With Advanced Cancer

NCT03794128 is registered in ClinicalTrials.gov with Gritstone bio, Inc. as lead sponsor.

NCT NCT03794128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03794128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational Feasibility Study for the Production of a Patient-Specific Neoantigen Cancer Vaccine and Screening Study for a Shared Neoantigen Cancer Vaccine in Patients With Advanced Cancer
Lead sponsor
Gritstone bio, Inc.
Phase
Observational
Overall status
Completed
Start date
July 25, 2018
Completion date
May 26, 2020
Enrollment
93 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, gastroesophageal adenocarcinoma, non small cell lung cancer, pancreatic ductal adenocarcinoma, urothelial carcinoma